Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$38.51 USD

38.51
608,213

+0.15 (0.39%)

Updated Aug 7, 2025 12:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Kite Pharma (KITE) Q2 Loss Narrower than Expected, Shares Up

by Zacks Equity Research

Kite Pharma, Inc. (KITE) reported narrower-than-expected loss in the second quarter of 2017 and beat estimates for sales. Shares of the biotech company rose 5.8% on Tuesday.

    Zacks Equity Research

    Epizyme (EPZM) Incurs Narrower-than-Expected Loss in Q2

    by Zacks Equity Research

    Epizyme, Inc. (EPZM) posted narrower-than-expected loss in Q2 as the company focuses on the development of tazemetostat.

      Zacks Equity Research

      What's in the Cards for Kite Pharma (KITE) in Q2 Earnings

      by Zacks Equity Research

      With no approved products in its portfolio, investor focus will primarily be on Kite Pharma, Inc.'s (KITE) cash burn and pipeline updates.

        Zacks Equity Research

        Exelixis (EXEL) Q2 Earnings, Sales Beat on Cabometyx Sales

        by Zacks Equity Research

        Exelixis' (EXEL) second-quarter results were impressive where in both earnings and sales beat estimates driven by strong uptake of Cabometyx.

          Zacks Equity Research

          Immune Design (IMDZ) Posts Narrower-than-Expected Loss in Q2

          by Zacks Equity Research

          Immune Design (IMDZ) incurred narrower-than-expected loss in Q2. Revenues missed expectations.

            Zacks Equity Research

            Clovis (CLVS) Q2 Loss Wider than Expected, Rubraca Impresses

            by Zacks Equity Research

            Clovis Oncology (CLVS) reported narrower year-over-year loss in the second quarter on the back of impressive Rubraca sales. The company is also actively working on Rubraca's label expansion.

              Zacks Equity Research

              Mylan (MYL) to Report Q2 Earnings: What's in the Cards?

              by Zacks Equity Research

              Mylan N.V. (MYL) is expected to focus on the performance of EpiPen and progress with the biosimilars pipeline during its second-quarter results.

                Zacks Equity Research

                What to Expect from Epizyme (EPZM) This Earnings Season?

                by Zacks Equity Research

                Epizyme, Inc. (EPZM) plans to focus on the development of its lead candidate tazemetostat in Q2.

                  Swarup Gupta headshot

                  Foreign Stock Roundup: GSK, Shell, AstraZeneca Beat on Earnings

                  by Swarup Gupta

                  Investors across the globe focused on earning numbers and the outcome of the Fed's policy meeting this week.

                    Zacks Equity Research

                    ImmunoGen (IMGN) Q2 Loss Narrows, Sales & Cash Outlook Up

                    by Zacks Equity Research

                    ImmunoGen's (IMGN) Q2 results report a narrower-than-expected loss with revenue beating the estimates. The company also significantly raises the cash and revenue guidance this quarter.

                      Zacks Equity Research

                      What's in the Cards for Immune Design (IMDZ) in Q2 Earnings?

                      by Zacks Equity Research

                      Immune Design Corp (IMDZ) is likely to focus on data from studies on its pipeline candidates- CMB305 and G100 in Q2.

                        Zacks Equity Research

                        Seattle Genetics (SGEN) Q2 Loss Narrower than Expected

                        by Zacks Equity Research

                        Seattle Genetics (SGEN) incurred narrower-than-expected loss in Q2 and provided an encouraging guidance for Adcetris.

                          Zacks Equity Research

                          Roche's (RHHBY) Sales Grow Y/Y in 1H17 on New Drug Launches

                          by Zacks Equity Research

                          Roche Holdings (RHHBY) delivered an impressive performance in 1H17 driven by new drug launches.

                            Zacks Equity Research

                            Can Prothena (PRTA) Deliver a Beat this Earnings Season?

                            by Zacks Equity Research

                            Prothena Corporation plc (PRTA) is expected to report second-quarter results next week and we expect investor focus on pipeline updates.

                              Zacks Equity Research

                              Ophthotech (OPHT) Q2 Loss Narrows, Focus Shifts to Zimura

                              by Zacks Equity Research

                              Ophthotech Corporation (OPHT) reported narrower-than-expected loss in the second quarter and also beat sales expectations.

                                Zacks Equity Research

                                Is a Beat in the Cards for ImmunoGen (IMGN) in Q2 Earnings?

                                by Zacks Equity Research

                                ImmunoGen has made significant progress with its ovarian cancer pipeline candidate. Let's see if the company can come up with a beat this earnings season.

                                  Zacks Equity Research

                                  Puma's (PBYI) Breast Cancer Drug Neratinib Gets FDA Approval

                                  by Zacks Equity Research

                                  Puma Biotechnology, Inc's (PBYI) lead breast cancer candidate neratinib is approved by FDA and is set to be commercially available in September under the brand name, Nerlynx.

                                    Zacks Equity Research

                                    Novartis Tops Q2 Earnings, Sandoz Faces Pricing Pressure

                                    by Zacks Equity Research

                                    Novartis AG (NVS) reported second-quarter 2017 core earnings of $1.22 per share, beating the Zacks Consensus Estimate of $1.16 but the recorded figure was a penny lower than the year-ago figure of $1.23.

                                      Zacks Equity Research

                                      The Zacks Analyst Blog Highlights: Infosys, Toyota Motor, Honda Motor, Taiwan Semiconductor Manufacturing and Roche Holdings

                                      by Zacks Equity Research

                                      The Zacks Analyst Blog Highlights: Infosys, Toyota Motor, Honda Motor, Taiwan Semiconductor Manufacturing and Roche Holdings

                                        Zacks Equity Research

                                        AstraZeneca (AZN) CEO Rumor Reportedly Ends, Shares Rise

                                        by Zacks Equity Research

                                        AstraZeneca plc shares rose after the company reportedly confirmed that its CEO is not quitting the company to join the generic drug-maker, Teva Pharmaceutical Industries Limited (TEVA).

                                          Swarup Gupta headshot

                                          Foreign Stock Roundup: Infosys Beats, Taiwan Semiconductor Misses

                                          by Swarup Gupta

                                          Dovish comments from Yellen helped global stocks post gains.

                                            Zacks Equity Research

                                            Mylan's Biosimilar Herceptin Gets FDA Advisory Committee Nod

                                            by Zacks Equity Research

                                            Mylan N.V. (MYL) and partner, Biocon Ltd. announced that the FDA Oncologic Drugs Advisory Committee (ODAC) unanimously recommended approval of its biosimilar version of Roche's (RHHBY) breast cancer drug Herceptin (trastuzumab).

                                              Zacks Equity Research

                                              Why Are Shares of Exelixis (EXEL) Up 77% So Far in 2017?

                                              by Zacks Equity Research

                                              Shares of Exelixis, Inc. (KITE) have gained almost 4.68% on Aug 12. The company's shares have rallied a whopping 77% this year so far, outperforming the 7.8% increase registered by the Zacks categorized industry during this period.

                                                Zacks Equity Research

                                                Alnylam (ALNY) Upgraded to Buy on Solid Pipeline Growth

                                                by Zacks Equity Research

                                                On Jul 11, Alnylam Pharmaceuticals Inc. (ALNY) was upgraded to a Zacks Rank #2 (Buy).

                                                  Zacks Equity Research

                                                  Roche (RHHBY) Announces Positive Data on Hemophilia A Drug

                                                  by Zacks Equity Research

                                                  Roche Holdings AG (RHHBY) announced positive data from the phase III study, HAVEN 1, on hemophilia A candidate emicizumab.